Gilead Sciences Inc. (NASDAQ:GILD) is one of the most undervalued quality stocks to buy according to hedge funds. On July 25, the European Medicines Agency’s Committee for Medicinal Products for Human ...

Bausch Health is acquiring DURECT primarily for its lead asset, called larsucosterol. This novel therapeutic molecule is an ...

The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...

The FDA has removed a pause in the use of Valneva’s chikungunya vaccine in older adults while tweaking the shot’s label with stricter language.

Key Points Non-GAAP earnings per share (EPS) of $2.25 in Q2 2025 far surpassed the analyst estimate of $0.32 and rose 923% year-over-year compared to Q2 2024 (non-GAAP adjusted diluted EPS per ADS).

Chinese authorities have taken action to curb the spread of chikungunya, a virus causing fever and joint pain.

The FDA reviews odronextamab's application for relapsed lymphoma, highlighting trial enrollment issues but confirming safety and efficacy.

Ocugen says it is on track to reshape the market for gene therapies against eye disorders over the next three years, by ...

To better detect cardiovascular diseases in people, researchers used high-performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS) to simultaneously quantify metabolites in human plasma ...

First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025; UK Clinical Trial Application (CTA) approval shortly follows U.S. IND clearance and granting of Euro ...